Clinical trials: Multiple Primary Neoplasm
Advanced Breast Cancer
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or…
- Trial name
- ALPINIST (NCT05631795)
- Testing
- Alpelisib, Fulvestrant
- Where
- 12 sites in India
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Multiple System Atrophy (MSA)
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA.
- Trial name
- NCT05923866
- Testing
- ONO-2808
- Where
- 35 sites in United States, Japan
- Volunteers
- 92 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Idebenone for Primary Progressive Multiple Sclerosis
Background: The Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) trial tested a new drug for multiple sclerosis. In the IPPoMS trial, participants took either idebenone or placebo.
- Trial name
- NCT01854359
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumors
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
The study allowed continued safety follow-up of patients who were on single agent dovitinib or dovitinib in combination with fulvestrant treatment in a Novartis-sponsored study which had met its primary endpoint and were…
- Trial name
- NCT02116803
- Testing
- dovitinib, fulvestrant
- Where
- 9 sites in United States, Austria and 5 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Heart Diseases, Diabetes Mellitus, Type 2
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.
- Conditions
- Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension
- Trial name
- CV-Homes (NCT06025721)
- Testing
- Cardiovascular Risk Homeless Support
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Katherine Vickery
Essential Thrombocythemia, Myelofibrosis
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm.
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera
- Trial name
- NCT03878199
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ischemia-Reperfusion Injury, Lung Transplantation
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved…
- Trial name
- NCT00224406
- Testing
- Repertaxin
- Where
- 6 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Dompé Farmaceutici S.p.A
Endometrial Cancer
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470067
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Osteoarthritis, Knee
A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS
The purpose of this study is to determine whether intra-articular (knee joint) administration of MEN16132 is effective reducing the pain from knee osteoarthritis.
- Trial name
- ALBATROSS (NCT01091116)
- Testing
- MEN16132 - 0.125 mg, MEN16132 - 0.25 mg, MEN16132 - 0.5 mg
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 423 people
- Sponsor
- Menarini Group
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02988401
- Testing
- Insulin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University
Hypogonadism, Primary Hypogonadism
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.
- Conditions
- Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Trial name
- TU (NCT00467870)
- Testing
- Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg
- Where
- United States
- Volunteers
- 531 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Osteoarthritis, Rheumatoid Arthritis
Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA
The study will evaluate the clinical performance of the rotating platform and fixed bearing implants through patient questionnaires, outcomes scoring and radiographic assessment.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis
- Trial name
- NCT00289107
- Testing
- Total Knee Arthroplasty, Total knee replacement
- Where
- 3 sites in United States
- Volunteers
- 149 people
- Sponsor
- DePuy Orthopaedics
Knee Osteoarthritis
A Study to Compare the Press Fit Condylar (P.F.C.) Sigma Rotating-platform High-flexion (RP-F) Versus the Press Fit Condylar (P.F.C.) Sigma Rotating-platform (RP) Knee Implants
The main objective of this study is to determine if the P.F.C. Sigma RP-F Knee delivers a greater post-operative range of motion (ROM) compared with the P.F.C. Sigma RP Knee in primary TKA.
- Trial name
- NCT00733369
- Testing
- PFC Sigma RP-F, PFC Sigma RP
- Where
- 2 sites in Spain, United Kingdom
- Volunteers
- 106 people
- Sponsor
- DePuy International
Hepatitis C, Medication Adherence
Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs
People who Inject Drugs (PWIDs) constitute 60% of the approximately 5 million people in the United States infected with hepatitis C virus (HCV).
- Trial name
- NCT03127358
- Testing
- AiCure, AiCure with gamification
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Albert Einstein College of Medicine
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Hyperglycemia, Hyperlipidemia
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Primary Aim: To test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates…
- Trial name
- NCT00910988
- Testing
- Olanzapine, Ziprasidone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine